Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Indivior Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units. This indicates that the company's active patent applications are being evaluated independently by different examiners, with no overlap in the personnel or the specific art units involved. The 2 pending office actions are the only current matters requiring active prosecution responses.
The busiest examiner is SOROUSH, LAYLA, who is managing 1 pending office action. With 2 pending office actions spread across 2 distinct examiners, the prosecution requires a case-specific approach for each matter. The use of 2 distinct art units suggests that the technologies, while both under the Biotechnology & Pharmaceuticals umbrella, are classified into different specialized groups within the patent office. Practitioners should prepare for 2 separate review processes, as the 2 distinct art units may apply different precedents or examination guidelines to the pending cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.4% | +43.6% |
| CONIGLIO, AUDREA JUNE BUCKLEY | 1 | 53.0% | +20.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174858 | Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose | CONIGLIO, AUDREA JUNE BUCKLEY | 120d overdue |
| 18753188 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18753188 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE | SOROUSH, LAYLA | 1622 | §103DP | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18174858 | Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose | CONIGLIO, AUDREA JUNE BUCKLEY | 1617 | §103 | Final Rejection | 120d overdue | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIndivior Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Layla Soroush has the most, with 1 of Indivior Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.